<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03689166</url>
  </required_header>
  <id_info>
    <org_study_id>PR(AMI)236/2016</org_study_id>
    <nct_id>NCT03689166</nct_id>
  </id_info>
  <brief_title>Effect of Probiotics on the Preterm Delivery Rate in Pregnant Women at High Risk for Preterm Birth</brief_title>
  <acronym>PROPEV</acronym>
  <official_title>Effect of Probiotics on the Preterm Delivery Rate (&lt; 37 Weeks) in Pregnant Women at High Risk for Preterm Birth (Pregnant Women With Threatened Preterm Labour): PROPEV TRIAL Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maternal-Infantil Vall d´Hebron Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maternal-Infantil Vall d´Hebron Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preterm birth (PB) continues to be the main cause of perinatal morbidity and mortality, with&#xD;
      emotional and economic consequences. Despite improvements in health, PB prevalence remains&#xD;
      stable, possibly due to complex causes such as maternal age, stress, multiparity, etc.&#xD;
      Shortening of the uterine cervix in early stages of gestation is a risk factor for PB. The&#xD;
      presence of abnormal vaginal microbiota in the early stages of pregnancy is als a risk factor&#xD;
      for PB. However, no studies have analysed the impact of probiotics (live microorganisms&#xD;
      which, in adequate amounts, confer a health benefit on the host) on the PB in high-risk PB&#xD;
      patients (pregnant women with threatened preterm delivery, i.e., uterine contractions and&#xD;
      cervical shortening, with a 30% PB risk before 34 weeks, and 50% PB prior to 37 weeks (&gt;&#xD;
      6-10% PB). Similarly, the effect of probiotics on vaginal flora dominated by lactic&#xD;
      acid-producing bacteria could be analysed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis&#xD;
&#xD;
        -  Pregnant women with threatened preterm labour (TPL) will present vaginal microbiome&#xD;
           different from those without TPL.&#xD;
&#xD;
        -  Treatment with probiotics will modify the vaginal microbioma of pregnant women with TPL.&#xD;
&#xD;
        -  The PB rate before 37 weeks in pregnant women with TPL who have received probiotics&#xD;
           since their diagnosis will be reduced by at least 30%.&#xD;
&#xD;
      Goals&#xD;
&#xD;
        -  To correlate the use of probiotics of pregnant women with TPL with the PB rate before 37&#xD;
           weeks.&#xD;
&#xD;
        -  To ascertain the PB rate before 28, 30, 32 and 34 weeks in both groups.&#xD;
&#xD;
        -  To assess neonatal morbidity between both groups.&#xD;
&#xD;
      Methods&#xD;
&#xD;
      Prospective, randomised, longitudinal, prospective, double-blind study.&#xD;
&#xD;
      Relevance&#xD;
&#xD;
      This study will determine whether the use of probiotics in pregnant women with TPL is&#xD;
      associated with a lower risk of PB before 37 weeks. If so, it would allow us to act on the&#xD;
      tertiary prevention of PB and treatment of TPL, the main cause of perinatal morbidity and&#xD;
      mortality in our setting. It will also facilitate understanding of the pathophysiology of PB,&#xD;
      influence of vaginal microbiota and the mechanism of action of probiotics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 23, 2017</start_date>
  <completion_date type="Anticipated">March 16, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 16, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Definition and design. Prospective, double-blind randomised study.&#xD;
Population Pregnant women admitted for TPL between weeks 24.0 and 34.6 of gestation at the participating centre.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blinded RCT</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Preterm birth rate &lt;37 weeks</measure>
    <time_frame>From 24 to 37 weeks</time_frame>
    <description>To evaluate the percentage of preterm birth in each group (in days of gestation)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preterm birth rate &lt;34 weeks</measure>
    <time_frame>From 24 to 34 weeks</time_frame>
    <description>To evaluate the percentage of preterm birth in each group (in days of gestation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preterm birth rate &lt;32 weeks</measure>
    <time_frame>From 24 to 32 weeks</time_frame>
    <description>To evaluate the percentage of preterm birth in each group (in days of gestation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preterm birth rate &lt;30 weeks</measure>
    <time_frame>From 24 to 30 weeks</time_frame>
    <description>To evaluate the percentage of preterm birth in each group (in days of gestation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preterm birth rate &lt;28 weeks</measure>
    <time_frame>From 24 to 38 weeks</time_frame>
    <description>To evaluate the percentage of preterm birth in each group (in days of gestation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intergroup neonatal morbidity</measure>
    <time_frame>First year of life of newborns</time_frame>
    <description>To assess neonatal morbidity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">206</enrollment>
  <condition>Preterm Birth</condition>
  <arm_group>
    <arm_group_label>Probiotics group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Probiotic drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group will receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <description>Reduce preterm birth with this dietary supplement</description>
    <arm_group_label>Probiotics group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Threatened preterm labour: regular clinical and cardiotography-registered uterine&#xD;
             dynamics, and cervical modifications (cervical shortening ≤ 25 mm between 24 and 29&#xD;
             weeks, and ≤ 15 mm between 30 and 34 weeks) according to our care protocol.&#xD;
&#xD;
          -  Single gestation.&#xD;
&#xD;
          -  Echographically-normal foetal morphology.&#xD;
&#xD;
          -  Minimum age 18 years.&#xD;
&#xD;
          -  Ability to understand informed consent.&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Multiple gestations.&#xD;
&#xD;
          -  Pregnant women with diagnosis of chorioamnionitis.&#xD;
&#xD;
          -  Cervical dilation.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maria Goya</last_name>
    <phone>934893085</phone>
    <email>maria.goya@vhir.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Vall d'Herbron</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria M Goya</last_name>
      <phone>934893185</phone>
      <email>mariagoya@mac.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 11, 2018</study_first_submitted>
  <study_first_submitted_qc>September 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2018</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Probiotics</keyword>
  <keyword>Preterm birth</keyword>
  <keyword>Threatened preterm labour</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>This study will allow us to determine whether the use of probiotics in pregnant women with TPL is associated with an increased risk of PB. If so, it would allow us to act on the tertiary prevention of PB and treatment of TPL, the main cause of perinatal morbidity and mortality in our setting. Similarly, it will facilitate understanding of the pathophysiology of PB, influence of vaginal microbiota and the mechanism of action of probiotics.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

